AzurRx Activates New Clinical Trial Sites In India For Gastrointestinal Infections COVID-19 Study

AzurRx BioPharma Inc. (AZRX) said that it has activated seven new clinical trial sites in India for phase 2 RESERVOIR Trial evaluating niclosamide for the treatment of COVID-19 gastrointestinal infections.

The phase 2 placebo-controlled clinical trial will confirm safety of FW-1022 and investigate its ability to remove SARS-CoV-2 virus from the GI tract.

The seven new clinical trial sites in India, together with the existing eleven sites in the U.S. and the five trial sites recently added in the Ukraine, brings the total number of RESERVOIR trial sites to twenty-three. AzurRx expects to report topline results during the first quarter of 2022.

The long-term observation data could indicate that niclosamide treatment has the potential to improve "long haul" COVID-19 symptoms.

FW-1022 is a niclosamide based small molecule drug which the Company's clinical trials may establish has anti-viral activity that is effective for the treatment of SARS-CoV-2 (COVID-19) gastrointestinal infections. FW-1022 is anticipated to be supplied as an oral immediate release tablet.

On Thursday, AzurRx BioPharma said that an independent data monitoring committee or DMC approved initiating patient enrollment in Part 2 of the ongoing RESERVOIR Phase 2 clinical trial evaluating FW-1022 as a treatment for COVID-19-related gastrointestinal infections.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Boeing expects Europe's commercial aviation fleet to need 8,705 new airplanes through 2040 to cater to the growing leisure travel market in the region and fleet replacements with more fuel-efficient models, according to the Boeing's 2021 Commercial Market Outlook (CMO), an annual forecast of long-term demand for commercial airplanes and services. The U.S. Food and Drug Administration authorized marketing of a software developed by Paige.AI, a provider of AI-based digital diagnostics, which could help pathologists to identify prostate cancer. The software, called Paige Prostate, is the first and only artificial intelligence or AI-based pathology product to receive FDA approval for in vitro diagnostic or IVD use in detecting cancer... General Mills (GIS) said its first-quarter top- and bottom-line results were ahead of its expectations. The company also reaffirmed its fiscal 2022 outlook. Looking forward, General Mills anticipates changes in consumer behaviors driven by the COVID-19 pandemic will result in ongoing elevated consumer...
Follow RTT